STOCK TITAN
  1. Home
  2. Sec-filings
  3. RVP
  4. [8-K] RETRACTABLE TECHNOLOGIES INC Reports Material Event

Retractable Technologies (NYSE: RVP) Q2 sales drop as $6.4M gain drives profit

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Retractable Technologies, Inc. reported weaker core operating results for the three and six months ended June 30, 2026. Second-quarter net sales were $7.2 million, down from $10.4 million a year earlier, with an unchanged operating loss of $5.1 million. For the first half of 2026, net sales were $14.4 million versus $18.7 million in 2025 and the operating loss widened to $11.3 million from $9.8 million, driven by lower EasyPoint® needle volumes and higher operating expenses, including donation expense.

Despite operating losses, second-quarter net income was $2.8 million, and the six-month net loss was $(1.4) million, both including a $6.4 million realized gain on the sale of equity securities. Domestic production rose to 42.4% of units manufactured in the first half of 2026 compared to 38% in 2025, and tariff expenses declined to $46 thousand in Q2 as mitigation and increased domestic production took effect. A previously disclosed April 2026 reduction in force is expected to generate future cost savings.

Positive

  • Net income of $2.8 million in Q2 2026 despite an operating loss, driven by a $6.4 million realized gain on the sale of equity securities.
  • Domestic production increased to 42.4% of units in the first half of 2026 from 38% in 2025, supporting tariff mitigation and supply-chain flexibility.
  • Tariff expenses fell to $46 thousand in Q2 2026 and $58 thousand for the first half, reflecting ongoing mitigation efforts and increased domestic production.
  • An April 2026 reduction in force is expected to result in cost savings in future periods, potentially easing operating expense pressure.

Negative

  • Second-quarter 2026 net sales declined to $7.2 million from $10.4 million, with overall unit sales down 36.4% due primarily to lower EasyPoint® needle demand and timing of orders.
  • For the first half of 2026, net sales fell to $14.4 million from $18.7 million and the operating loss widened to $11.3 million from $9.8 million, reflecting lower revenues and higher operating expenses.
  • Domestic revenues decreased 30.8% and domestic unit sales decreased 35.1% in Q2 2026, while international revenues also declined and the company notes uncertainty around the timing of future international orders.

Filing Explained

Future international orders and tariff costs remain unresolved.

This August 14 Form 8-K reports the June 30 results and leaves the timing of future international orders and the effect of tariffs on future costs unresolved.

The latest supplied liquidity record, dated March 31, 2026, shows cash and equivalents of $2,765,893 and operating cash flow of negative $1,368,129.

The filing specifically identifies future international-order timing and tariff costs as items subject to future-period uncertainty. Future-period filings can be checked for international order timing and tariff expense.

Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Q2 2026 Net Sales $7.2 million Total net sales for the second quarter of 2026
Q2 2025 Net Sales $10.4 million Total net sales for the second quarter of 2025 for comparison
Q2 2026 Operating Loss $5.1 million Loss from operations for the three months ended June 30, 2026
H1 2026 Net Sales $14.4 million Net sales for the six months ended June 30, 2026
H1 2026 Operating Loss $11.3 million Operating loss for the six months ended June 30, 2026
Realized Gain on Equity Securities $6.4 million Gain from sale of equity securities in the second quarter of 2026
Q2 2026 Net Income $2.8 million Net income for the three months ended June 30, 2026, including realized gain
Domestic Production Share H1 2026 42.4% Percentage of units manufactured domestically during the first six months of 2026
operating loss financial
"reports total net sales of $7.2 million for the second quarter of 2026 and an operating loss of $5.1 million"
Operating loss occurs when a company’s regular business activities—sales of goods or services—bring in less money than it costs to run the business, like a shop whose daily sales don’t cover rent and wages. For investors, it signals that the core business isn’t currently profitable, which can increase cash burn, affect future dividends or financing needs, and change how the company’s value and risk are judged.
realized gain financial
"The realized gain from the sale of equity was $6.4 million in the second quarter of 2026"
Profit you actually lock in when you sell an investment: it’s the difference between what you received from the sale and what you originally paid. Like selling a used car for more than you paid, a realized gain turns a paper increase into cash that can be spent or reinvested, and it often creates tax obligations, so investors watch realized gains to understand true returns and potential tax impact.
unrealized loss on debt securities financial
"The unrealized loss on debt securities was $179 thousand for the second quarter of 2026"
reduction in force other
"a reduction in force in April 2026 is expected to result in cost savings in future periods"
A reduction in force is an organized cutback in a company's workforce—commonly known as layoffs—intended to lower costs or reshape operations. Like trimming a household budget or pruning a garden, it can improve long-term financial health but often brings one-time costs, reduced capacity, and morale or execution risks that can affect revenue, expenses, and the company’s stock performance. Investors watch these moves for signals about future profitability and operational stability.
tariffs financial
"Tariffs may continue to materially impact our costs in future periods"
Tariffs are taxes imposed by a government on goods imported from other countries. They increase the cost of those goods, which can lead to higher prices for consumers and impact international trade. For investors, tariffs matter because they can influence the profitability of companies, affect supply chains, and shift economic stability across different regions.
domestic production financial
"Domestic production increased to 42.4% of the units manufactured during the first six months of 2026"
Q2 2026 Net Sales $7.2 million compared to $10.4 million for the same period in 2025
Q2 2026 Operating Loss $5.1 million same as operating loss for the second quarter of 2025
H1 2026 Net Sales $14.4 million compared to $18.7 million for the first half of 2025
H1 2026 Operating Loss $11.3 million compared to operating loss of approximately $9.8 million in 2025
Q2 2026 Net Income $2.8 million includes a $6.4 million realized gain on sale of equity securities
H1 2026 Net Income (Loss) $(1.4) million includes the $6.4 million realized gain on sale of equity securities

FAQ

How did Retractable Technologies (RVP) perform in Q2 2026?
Retractable Technologies reported Q2 2026 net sales of $7.2 million and an operating loss of $5.1 million. A $6.4 million realized gain on equity securities led to net income of $2.8 million for the quarter.

What were Retractable Technologies (RVP) results for the first half of 2026?
For the six months ended June 30, 2026, Retractable posted net sales of $14.4 million and an operating loss of $11.3 million. Including a $6.4 million realized gain, the company reported a net loss of $(1.4) million.

Why did Retractable Technologies (RVP) sales decline in 2026?
Sales declined largely due to lower EasyPoint® needle unit sales and timing of customer orders. Net sales fell to $7.2 million in Q2 and $14.4 million in the first half, compared with $10.4 million and $18.7 million in 2025.

What cost-control or efficiency measures has Retractable Technologies (RVP) implemented?
The company increased domestic production to 42.4% of units in the first half of 2026 and reduced tariff expenses to $46 thousand in Q2. A reduction in force in April 2026 is expected to provide additional cost savings.

What impact did securities investments have on Retractable Technologies (RVP) in 2026?
Retractable recorded a $6.4 million realized gain from the sale of equity securities in Q2 2026, plus an $13 thousand unrealized gain on debt securities for the first half, significantly affecting reported net income and loss.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
false 0000946563 0000946563 2026-08-14 2026-08-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) August 14, 2026

 

Retractable Technologies, Inc.

(Exact name of registrant as specified in its charter)

 

Texas   001-16465 75-2599762
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)

 

511 Lobo Lane, Little Elm, Texas 75068-5295
(Address of principal executive offices) (Zip Code)

 

Registrant's telephone number, including area code (972) 294-1010

 

None

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock RVP NYSE American

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

  Emerging growth company  ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

 

 

Item 8.01Other Events.

 

On August 14, 2026, the Company issued a press release, a copy of which is attached to this Form 8-K as Exhibit 99, announcing results for the periods ended June 30, 2026.

 

Item 9.01Financial Statements and Exhibits.

 

(d) Exhibits

 

99Press release announcing results for the periods ended June 30, 2026.

 

104Cover Page Interactive Date File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

DATE: August 14, 2026 RETRACTABLE TECHNOLOGIES, INC.
  (Registrant)
     
  BY: /s/ John W. Fort III
    JOHN W. FORT III
    VICE PRESIDENT, CHIEF FINANCIAL OFFICER, AND CHIEF ACCOUNTING OFFICER

 

 

 

 

Exhibit 99

 

RETRACTABLE TECHNOLOGIES, INC. RESULTS FOR THE PERIODS ENDED JUNE 30, 2026

 

LITTLE ELM, TEXAS, August 14, 2026 — Retractable Technologies, Inc. (NYSE American: RVP) reports total net sales of $7.2 million for the second quarter of 2026 and an operating loss of $5.1 million for the period, as compared to total net sales for the same period last year of $10.4 million and an operating loss of $5.1 million.  For the first half of the year, net sales were $14.4 million and operating losses were $11.3 million as compared to 2025 net revenues of $18.7 million and operating losses of $9.8 million.

 

While the majority of flu season sales typically occur in the third quarter, in 2025, purchasing patterns differed with unusually high unit sales related to flu season products in the second quarter of 2025, impacting comparability to second quarter 2026 unit sales related to flu season products, which follows a more traditional purchasing pattern.

 

Domestic production increased to 42.4% of the units manufactured during the first six months of 2026 compared to 38% of units produced domestically for the first six months of 2025. Additionally, as previously reported, a reduction in force in April 2026 is expected to result in cost savings in future periods.

 

Our net income (loss) for the three and six months ended June 30, 2026 was $2.8 million and $(1.4) million, respectively, including a $6.4 million gain on the sale of equity securities in the second quarter of 2026.

 

Comparison of Three Months Ended June 30, 2026 and June 30, 2025

 

Domestic sales accounted for 81.6% and 81.3% of total revenues for the three months ended June 30, 2026 and 2025, respectively. Domestic revenues decreased 30.8%, while domestic unit sales decreased 35.1%. Domestic unit sales represented 70.3% of total unit sales for the three months ended June 30, 2026 compared to 68.9% for the same period last year. The decrease in sales and units was primarily due to the timing of EasyPoint® product orders from certain customers, which can fluctuate between periods based on customer purchasing patterns.

 

International revenues for the three months ended June 30, 2026 decreased 32.2% compared to the same period in 2025. The decrease in international sales was primarily driven by a decrease in EasyPoint® needle sales. Traditionally, international sales carry lower average selling prices compared to our domestic sales. There remains uncertainty regarding the timing of future international orders.

 

Overall, units sales decreased 36.4% due to a decrease in EasyPoint® needle sales.

 

Cost of manufactured product decreased 34.7% compared to the same period last year primarily due to a decrease in sales. Royalty expense decreased 20.8% due to the decrease in gross sales.

 

Tariffs may continue to materially impact our costs in future periods. Approximately $46 thousand was spent on tariff expenses in the second quarter of 2026. The reduction in tariff costs compared to prior periods is attributable to ongoing mitigation efforts, including strategic sourcing decisions and increased domestic production. These costs are included in Cost of manufactured product.

 

Operating expenses remained consistent in the three months ended June 30, 2026 and 2025.

 

The loss from operations was $5.1 million for the three months ended June 30, 2026 and 2025.

 

The unrealized loss on debt securities was $179 thousand for the second quarter of 2026 due to the decreased market values of those securities. The realized gain from the sale of equity was $6.4 million in the second quarter of 2026.

 

The provision for income taxes was $1.8 thousand for the three months ended June 30, 2026 and 2025.

 

 

 

 

Comparison of Six Months Ended June 30, 2026 and June 30, 2025

 

Domestic sales accounted for 82.2% and 85.0% of total revenues for the six months ended June 30, 2026 and 2025, respectively. Domestic revenues decreased 25.8%, while domestic unit sales decreased 25.0%. Domestic unit sales represented 71.2% of total unit sales for the six months ended June 30, 2026 compared to 74.9% for the same period last year. The decrease in sales was primarily due to a decrease in EasyPoint® needle unit sales.

 

International revenues for the six months ended June 30, 2026 decreased 9.3% compared to the same period in 2025. Traditionally, international sales carry lower average selling prices compared to our domestic sales. There remains uncertainty regarding the timing of future international orders.

 

Overall, units sales decreased 21%.

 

Cost of manufactured product decreased 20.8% compared to the same period last year primarily due to a decrease in units sold. Royalty expense decreased 14.4% due to the decrease in gross sales.

 

Tariffs may continue to materially impact our costs in future periods. Approximately $58 thousand was spent on tariff expenses in the first six months of 2026. The reduction in tariff costs compared to prior periods is attributable to ongoing mitigation efforts, including strategic sourcing decisions and increased domestic production. These costs are included in Cost of manufactured product.

 

Operating expenses increased 10.0% primarily due to donation expense.

 

The loss from operations was $11.3 million compared to a loss of approximately $9.8 million for the same period last year. The increase in loss from operations was primarily driven by a decrease in revenue and increase in operating expenses due to donation expense.

 

The unrealized gain on debt securities was $13 thousand for the six months ended June 30, 2026 due to the increased market values of those securities. The realized gain from the sale of equity was $6.4 million in the first six months of 2026.

 

The provision for income taxes was $3.7 thousand as compared to a benefit for income taxes of $288 thousand for the same period in 2025. The change is primarily due to a decrease in the net loss in the current period.

 

ABOUT RETRACTABLE

 

Retractable manufactures and markets VanishPoint® and Patient Safe® safety medical products and the EasyPoint® needle. The VanishPoint® syringe, blood collection, and IV catheter products are designed to prevent needlestick injuries and product reuse by retracting the needle directly from the patient, effectively reducing exposure to the contaminated needle. Patient Safe® syringes are uniquely designed to reduce the risk of bloodstream infections resulting from catheter hub contamination. The EasyPoint® is a retractable needle that can be used with luer lock syringes, luer slip syringes, and prefilled syringes to give injections. The EasyPoint® needle also can be used to aspirate fluids and for blood collection. Retractable's products are distributed by various specialty and general line distributors.

 

For more information on Retractable, visit its website at www.retractable.com.

 

Forward-looking statements in this press release are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995 and reflect Retractable's current views with respect to future events. Retractable believes that the expectations reflected in such forward-looking statements are accurate. However, Retractable cannot assure you that such expectations will materialize. Actual future performance could differ materially from such statements.

 

 

 

 

Factors that could cause or contribute to such differences include, but are not limited to: tariffs; material changes in demand; Retractable's ability to maintain liquidity; Retractable's maintenance of patent protection; Retractable's ability to maintain favorable third party manufacturing and supplier arrangements and relationships; foreign trade risk; Retractable's ability to access the market; production costs; the impact of larger market players in providing devices to the safety market; and other risks and uncertainties that are detailed from time to time in Retractable's periodic reports filed with the U.S. Securities and Exchange Commission.

 

Retractable Technologies, Inc.

John W. Fort III, 888-806-2626 or 972-294-1010

Vice President, Chief Financial Officer, and Chief Accounting Officer

 

 

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents

Press Releases

Other Documents